Cumberland Pharmaceuticals Reports Q1 Net Loss of $3.3M Amidst Pending $100M Apotex Deal
CPIX has more than doubled off its 52-week low of $1.85 on light trading volume (0.3× avg).
Summary
Cumberland Pharmaceuticals reported Q1 2026 net revenues of $9.1 million and a net loss of $3.3 million, or $0.22 per share. This earnings report also reiterated the previously announced strategic transaction to sell its commercial product portfolio to Apotex for $100 million in cash, which was initially disclosed on April 23, 2026. The Q1 net loss is a material financial update for the company, especially following its "strong 2025 financial results." While the $100 million transaction with Apotex is a significant positive for the company's future, these Q1 results reflect the company's performance prior to the closing of that deal and highlight its current operational state. Investors will monitor the progress of the Apotex transaction, which is subject to shareholder approval, and the company's continued focus on its development programs, particularly ifetroban.
At the time of this announcement, CPIX was trading at $4.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.1M. The 52-week trading range was $1.85 to $6.27. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.